Table 3.
Univariate and multivariate analyses of predictive factors for relapse
| No. (%) | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| p | Relative risk (Exp[b]) | p | Relative risk (Exp[b]) | ||
| Sex | |||||
| M | 32 (57.1) | ||||
| F | 24 (42.9) | 0.26 | 0.41 | 0.18 | 0.34 |
| Age at HDC/auto-SCT | |||||
| < 10 | 23 (41.1) | ||||
| ≥ 10 | 33 (58.9) | 0.29 | 2.31 | 0.31 | 2.39 |
| Histology | |||||
| Hodgkin’s disease | 12 (21.4) | ||||
| Non-Hodgkin’s lymphoma | 44 (78.6) | 0.73 | 0.76 | ||
| Stage | |||||
| I–III | 29 (51.8) | ||||
| IV | 27 (48.2) | 0.54 | 0.63 | ||
| Indication for HDC/auto-SCT | |||||
| PR after induction CTx | 44 (78.6) | ||||
| Relapse | 8 (14.3) | 0.81 | 0.79 | ||
| NK/T-cell lymphoma | 4 (7.1) | 0.48 | 2.16 | ||
| Pre-HDC/auto-SCT disease status | |||||
| CR | 48 (85.7) | ||||
| PR | 8 (14.3) | 0.068 | 3.96 | 0.045 | 4.85 |
CR complete response, CTx chemotherapy, HDC/auto-SCT high-dose chemotherapy and autologous stem cell transplantation, PR partial response